Canagliflozin and Renal Outcomes in Diabetic Nephropathy.

[1]  B. Zinman,et al.  Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. , 2019, The New England journal of medicine.

[2]  N. Stefan,et al.  Effect of SGLT2 inhibitors on body composition, fluid status and renin–angiotensin–aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy , 2019, Cardiovascular Diabetology.

[3]  K. Mahaffey,et al.  Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program , 2019, Diabetologia.

[4]  Marc P. Bonaca,et al.  SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials , 2019, The Lancet.

[5]  V. Vallon,et al.  Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition , 2017, Diabetologia.

[6]  M. Woodward,et al.  Past Decline Versus Current eGFR and Subsequent Mortality Risk. , 2016, Journal of the American Society of Nephrology : JASN.

[7]  L. Blonde,et al.  Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks , 2016, Postgraduate medicine.

[8]  R. DeFronzo,et al.  Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus. , 2015, American journal of physiology. Renal physiology.

[9]  G. Navis,et al.  Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. , 2014, The lancet. Diabetes & endocrinology.

[10]  C. McCulloch,et al.  Signs and symptoms associated with earlier dialysis initiation in nursing home residents. , 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[11]  B. Brenner,et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.

[12]  Uk-Prospective-Diabetes-Study-Group.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.

[13]  Microvascular Complications and Foot Care : Standards of Medical Care in Diabetes d 2019 , 2018 .

[14]  N. Ruderman.  Muscle amino acid metabolism and gluconeogenesis. , 1975, Annual review of medicine.